74 results about "Secretory antibody" patented technology

The invention discloses a preparation method of an anti-bisphenol A monoclonal antibody. The preparation method comprises the following steps of: combining bisphenol A and a macromolecule carrier protein to prepare an artificial immunity antigen and a coating antigen; preparing splenocyte suspension from a bisphenol A artificial immunity antigen immunity mouse; fusing the mouse splenocyte and mouse myeloma cells SP2/0 in the presence of polyethylene glycol; detecting by hybridoma technology and subcloning for many times to obtain positive hybridoma cells which can stably secrete bisphenol A antibody, wherein the secreted antibody belongs to the IgG1 subclass; and establishing a bisphenol A indirect competition ELISA (Enzyme-Linked Immunosorbent Assay) test by utilizing the monoclonal antibody secreted by cell lines with high antibodytiter, wherein the minimum limit of detection can reach 0.324ng/mL. The antibody has no cross reaction with compounds with benzene ring structures, such as benzene, phenol, tert-butylphenol, p-hydroxylphengl, o-hydroxybenzoic acid and the like, has strong specificity and can be used for immunity detection of bisphenol A.

The invention provides a PED (Porcine Epedemic Diarrhea) inactivated vaccine and a preparation method thereof and relates to the field of biopharmacy. The PED inactivated vaccine comprises inactivated PEDV (Porcine Epedemic Diarrhea Virus), and is characterized in that the PED inactivated vaccine comprises 0.05-10 mg/mL Beta-glucosylceramide, 0.1-21 mg/mL monophosphoryl lipid A, 1.5-125 mg/mL muramyl dipeptide and 0.7-4.5 mg/mL Beta-glucan. According to the ingredients of the PED inactivated vaccine, Beta-glucosylceramide, monophosphoryl phosphoryl lipid A, muramyl dipeptide and Beta-glucan have the synergistic effect, the immune response of animals to antigens in the vaccine is significantly improved, the immune window phase is shortened, the antibody production duration of the animal body is obviously prolonged, the serum antibody level is improved, and the level of total intestinal mucosa secretory antibodies (the total SIgA) is improved.

The invention relates to a CD19 targeted chimeric antigen receptor and an application thereof, and particularly provides a polynucleotide sequence, which is selected from: (1) a polynucleotide sequence which contains, in a successively connected manner, an encoding sequence of anti-CD19 single-chain antibody, an encoding sequence of human CD8[alpha] hinge zone, an encoding sequence of human CD28 transmembrane zone, an encoding sequence of human CD28 intracellular zone, an encoding sequence of human CD3 [zeta] intracellular zone, and optionally, a fraction, which contains an extracellular domain III and an extracellular domain IV of EGFR, and an encoding sequence of anti-human PD1 sequence fraction; and (2) a complementary sequence of the polynucleotide sequence (1). The invention also provides related fusion proteins, a carrier containing the encoding sequences, and applications of the fusion proteins, encoding sequences and carrier. The CAR-T cell has strong killing effect on specifictumor cells, and can reach more than 90% in killing efficiency on the specific tumor cells under the multiplicity of infection of 1:2. The CAR-T cell can secrete the PD1 antibody and has regulation effect on immunosuppression micro-environments.

The invention discloses an anti-human CEACAM5 monoclonal antibody and a preparation method and application thereof, and the anti-human CEACAM5 monoclonal antibody is produced by a mouse hybridoma cellline with the accession number CCTCC NO: C2016129. The preparation method comprises the following steps: S1, immunizing a mouse with whole cell protein, lysed by human gastric cancer cells, as an immunogen; S2, fusing spleen cells of the immunized mouse obtained in the step S1 with mouse myeloma cells; S3, selecting a hybridoma cell line stably secreting antibodies after cell cloning occurs during the cell fusing in the step 2; and S4, preparing the anti-human CEACAM5 monoclonal antibody from the hybridoma cell line stably secreting the antibodies obtained in the step 3. The monoclonal antibody can be used to prepare a composition for treating a malignant tumor. The anti-human CEACAM5 monoclonal antibody can be widely used in various routine operations such as flow cytometry, immunohistochemical staining and immunoprecipitation.

The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof.

The invention relates to an anti-H7 subtype avian influenza virus monoclonal antibody and application thereof, belonging to the technical field of biology. A hybridoma cell strain 5D2 is screened; the hemagglutination inhibition (HI) titer of the rat ascites antibody prepared from the hybridoma cell strain 5D2 for H7-AIV is 11log2, and the ELISA titer is 2*10<5>. The anti-H7 monoclonal antibody secreted by the hybridoma cell strain has high HI and ELISA titer; the colloidal gold immunochromatography detection test strip assembled by the anti-H7 monoclonal antibody has high specificity, except that the result for H7-AIV is positive, the results for the other avian viruses are negative; the anti-H7 monoclonal antibody can be used for on-site diagnosis on fowl, mammals or the like infected by H7-AIV; and the result can come out within 10 minutes, is visual, and can be easily judged with naked eyes. The sensitivity of the diagnosis kit assembled by the hybridoma cell strain secretory antibody is not lowered after the diagnosis kit is stored for one year, so the diagnosis kit has favorable stability.

The invention discloses a preparation method of an alpha-glucan antigen and a specificity monoclonal antibody. The preparation method of the antigen comprises the following steps: mixing alpha-glucan and protein; dissolving with water; regulating the pH of solution to 5-8; carrying out freeze drying, and grinding into powder; putting the powder in the environment with constant temperature of 50-60DEG C and relative humidity of 60-90%; reacting for at least three days to obtain the alpha-glucan antigen. The preparation method of the antibody comprises the following steps: mixing the prepared antigen with an adjuvant, emulsifying the mixture, and injecting the emulsified mixture into animal bodies; blending the splenocyte and oncocyte of the animal body with the high serum valence to obtain a hybridoma cell capable of secreting the antibody; and producing the antibody by the hybridoma cell or with an ascites method. The antibody prepared by the method has high immunogenicity, and can be used for effectively inducing to generate immune response to obtain the antibody with the excellent property. The antibody obtained by the method provided by the invention can be subjected to specificity reaction with the alpha-glucan to generate macroscopic precipitates, and the antibody has high valence and can be used for the quantitative analysis on the alpha-glucan.

The invention discloses an antigen for preparing a listeria monocytogenes monoclonal antibody. An amino acid sequence of the antigen is shown in SEQ NO.1. According to the antigen, a specific surfaceprotein fragment capable of representing listeria monocytogenes is obtained through screening and experimental verification, the specific surface protein fragment is used as an antigen sequence to obtain a positive cell line by cell fusion, after three rounds of subcloning, an indirect ELISA method is used to detect the positive strains and detect a cross-reaction between a secreted antibody and other food-borne pathogenic strains to obtain a specific fusion cell line, finally, a monoclonal hybridoma cell with high titer and good specificity is obtained, and the mouse monoclonal antibody is prepared and has a titer of 810000 and good specificity. The monoclonal antibody provided by the invention has higher sensitivity, good specificity and strong stability.

A monoclonal secretory IgA antibody, which binds to and neutralizes human TNFα. The secretory antibody is useful in treating a variety of inflammatory conditions in humans.

The invention discloses a preparation method and application of gene-edited CAR (Chimeric Antigen Receptor)-T cells capable of secreting a cell factor or an antibody. The method for preparing the CAR-T cells comprises the step of transfecting plasmid vectors containing gene-edited plasmids and CAR modification to T cells. The CAR-T cells provided by the invention are used for knocking out negativeregulator genes on surfaces of the T cells through gene editing and gene modification, integrating a single-chain antibody for identifying a tumor cell surface antigen and an expression frame for secreting the cell factor or secreting the antibody into the T cells and continuously expressing in the T cells, so that the T cells returned back are prevented from being inhibited by a tumor microenvironment and a better killing effect on the tumor cells is realized.

The invention belongs to the field of biological products, and in particular relates to an inactivated vaccine for porcine epidemic diarrhea virus which is produced by ST cells and a preparation method of the inactivated vaccine. The method comprises four steps, namely amplification culture of the ST cells, virus inoculation, multiplying of vaccine producing virus liquid, and product preparation. The vaccine, which is produced by the method, is high in immunization level and short in immunological window phase; an immunity period is obviously prolonged; and total secretory antibody (total SIgA) in intestinal mucosa is remarkably improved.

The invention discloses a secretory target Lewis-Y CAR-T cell, which comprises a CAR-T cell which targets Lewis-Y and secretes IL12 cytokine; a CAR-T cell which targets Lewis-Y and secretes PD-1 antibodies. The invention further discloses a preparation method of the CAR-T cell of the secretory target Lewis-Y and an application of the CAR-T cell in preparing an anti-tumor cell therapy medicament. The PD-1 antibody secreted by the CAR-T cell is specifically combined with the PD-1 on the surface of the T cell, thereby blocking the inhibition reaction of the PD-1/PD-L1 signal on the activity of the T cell, so that the effective inhibition of growth of tumor cells for a long time by the CAR-T cell is facilitated; the IL12 cell factor secreted by the CAR-T cell can act on immunosuppressive cellsin tumor inhibitory immune microenvironment, so that the immunosuppressive capacity of the immunosuppressive cells is reduced, and the killing effect of the CAR-T cell is further enhanced.